Click here to view 2016 Race Flyer
To download PDF documents:
2016 Annual Teal There's a Cure - Race Registration
Thank you for your interest in the 8th Annual Maureen T. O'Hara Teal There's A Cure 5K.
July 4, 2016 race registration will be posted when available. View the 2016 race information now.
Bob McGray, PhD
Roswell Park Cancer Institute
Your 2015 Support Making A Difference
Thank you everyone for supporting our 7th Annual Maureen T. O’Hara “Teal There’s A Cure” 5K Run/Walk. Because of your support we were able to continue with last year’s study, through OCRF’s Partners in Science, research project “Combination Oncolytic Virotherapy/ACT for Ovarian Cancer Treatment,” led by Bob McGray, PhD, at Roswell Park Cancer Institute. We made another donation to the study after the race of $25,000.00. It brings our total donation to $55,000.00 for that research project. That is possible because of all of you. THANK YOU.
We also made donations to: Ovarian Cancer Research Fund Alliance, GRACE’S CNY Support Group for Women with Ovarian & Gynecologic Cancers and Upstate Cancer Center.
Mark your calendars for the 8th Annual Maureen T. O’Hara “Teal There’s A Cure” Monday, July 4th, 2016. See you all then.
Thanks so much for your continued support!
The O’Hara Family & Teal Committee
Combination oncolytic virotherapy/ACT for ovarian cancer treatment
"Through research funded by the OCRF and Teal There’s a Cure, we are investigating strategies that combine oncolytic virotherapy (OV) and adoptive T cell transfer (ACT) for the treatment of metastatic ovarian cancer. ACT, a potent form of immunotherapy that harnesses the power of a patient’s own T cells to be instructed to seek out, recognize, and kill tumor cells, has shown promise in early clinical trials. However responses are often only temporary with eventual tumor relapse. Through the use of OV, a term given to viruses that can selectively infect and kill tumor cells, while also acting to promote inflammation within the tumor, we believe the benefit of ACT for cancer treatment can be further improved. Since receiving research funds in early 2015, we have made progress in a number of key areas that are helping to propel our research forward. Using a mouse model of aggressive metastatic ovarian cancer, we have identified that OV can be delivered in combination with ACT as a means of improving the effectiveness of tumor-recognizing T cells. When OV is delivered along with ACT, we have observed improved long-term survival of mice treated with this combination therapy compared to either OV or ACT treatment alone, with a subset of mice appearing to be completely cured by the OV + ACT combination. Our data suggests that the improved effectiveness of this treatment is due, at least in part, to the ability of OV to promote trafficking of tumor-specific T cells into tumors, a process which is required for tumor cell killing by T cells, but which is very inefficient when ACT is administered as a single therapy. Our current studies are focused on understanding the processes within the tumor that drive the improved infiltration of T cells following OV delivery and whether the timing of OV treatment dramatically impacts upon the ability of transferred T cells to traffic into the tumor. In addition, using a clinically-relevant approach to generating tumor-specific T cells, termed T cell engineering, we have developed two mouse models that target tumor antigens that are relevant to the clinical treatment of ovarian cancer using ACT. We are in the process of testing these engineered T cells using OV + ACT combinations as a step towards clinical translation. Lastly, we are now investigating mechanisms of immune suppression that may act to limit the duration of effective tumor attack by the transferred T cells and whether additional interventions may be required to further improve OV + ACT combination treatments. Overall, we are well on our way to understanding how best to use OV to compliment ACT therapies for ovarian cancer treatment, studies which would not have been possible without the generous support of OCRF and Teal There’s a Cure."
- AJ Robert McGray, PhD
Bob McGray, PhD
Roswell Park Cancer Institute
"Combination Oncolytic Virotherapy/ACT for Ovarian Cancer Treatment"
Raphael Ceccaldi, PhD, PharmD
Dana-Farber Cancer Institute
"A Bioinformatic Screen Identifies POLQ Overexpression in Ovarian Cancers"
Kate Lawrenson, PhD
University of Southern California
"Modeling Stem Cells Origins of Ephithelian Ovarian Carcinomas"
Gregory Motz, PhD
University of Pennsylvania
"Advancing T-Cell Adoptive Immunotherapy for Ovarian Cancer"